Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, and is the most common neurological disorder affecting young adults[@b1]. Current evidence implicates roles for both environmental and genetic factors in the onset and progression of the disease[@b2][@b3][@b4]. The importance of genetic factors in MS was recognized early in the study of the disease, and is best illustrated by observations of strong familial clustering and a significantly increased risk in first-degree relatives[@b5][@b6][@b7]. Further support for the role of genes in MS comes from studies of monozygotic and dizygotic twins, which also indicate a strong genetic component; however, heritability estimates from these studies range from roughly 25% to 75%[@b8][@b9][@b10][@b11]. Alleles of the major histocompatibility complex (MHC) are so far known to make the single strongest contribution to MS susceptibility[@b12]. In addition, many loci of more modest effect have also recently been identified in genome-wide association studies (GWASs)[@b13][@b14][@b15][@b16]. While risk alleles at the MHC are thought to represent a significant proportion of MS genetic susceptibility[@b13], the contribution of variants outside of the MHC, specifically those represented by single nucleotide polymorphisms (SNPs) genotyped by GWASs, has not been extensively explored. To investigate in more detail the role of common GWAS variants in MS susceptibility, we used publically available genotype data from the United Kingdom (UK) MS patient and control cohorts[@b16] and a recently described approach that assesses contributions made by all genotyped SNPs, rather than solely risk loci that reach genome-wide significance[@b17][@b18][@b19][@b20]. From this analysis we show that approximately 30% of the genetic variation in liability to MS is directly explained by variants represented by current GWAS arrays.

Results
=======

For this study, we used genome-wide genotype data for 475,806 autosomal SNPs collected from 1,854 MS cases and 5,164 controls sampled from the UK[@b16]. After assessing the relatedness between individuals, and thus accounting for effects of population structure, we first estimated the proportion of variance explained by all autosomal SNPs simultaneously. This analysis revealed that 30.7% (standard error (SE) = 2.05%) of the variance in liability to MS is accounted for by SNPs in this dataset.

We next partitioned SNPs by autosome and recalculated the proportion of variance explained by variants found on each chromosome ([Table 1](#t1){ref-type="table"}); estimated values ranged from \~0--8% per chromosome. Not surprisingly, given the known contribution of the MHC, which is located on chromosome 6, SNPs on this chromosome account for 8.11% of the variance (SE = 0.72%). By calculating the proportion of the genome represented by each chromosome (not including the length of sex chromosomes), we tested for a correlation between the variance explained by each chromosome relative to its size, excluding chromosome 6 ([Figure 1](#f1){ref-type="fig"}). Although it was evident that several of the smaller chromosomes contributed less to the overall variance than several of the larger chromosomes, the overall trend was not significant (r = 0.336, *P* = 0.136). To assess the contribution made by common versus rare variants, we also binned SNPs based on minor allele frequency (MAF; [Figure 2](#f2){ref-type="fig"}). From this, we observed that common variants (MAF \> 0.1; \~4--6%), which are most abundantly sampled on GWAS arrays, make a greater contribution than rare variants (MAF \< 0.1; \~2.8%). However, because of the unequal number of SNPs in each bin, we also binned SNPs by quintile ([Figure 3](#f3){ref-type="fig"}). Based on this analysis, we found that all quintiles displayed an equivalent variance, highlighting that no particular frequency of MAF makes a larger or smaller contribution to MS, and that all should be captured and tested.

Lastly, we carried out an association analysis using only the UK GWAS data. We identified 15 associated autosomal SNPs in this cohort outside of the MHC with *P* values \<1×10^−5^. These SNPs, their positions (hg18; NCBI Build 36.1), and the nearest RefSeq gene to each are listed in [Table 2](#t2){ref-type="table"}. Using association analysis data, we also examined the contribution made by all associated SNPs to the observed variance after binning by *P* value, including those SNPs within the MHC ([Table 3](#t3){ref-type="table"}).

Discussion
==========

Using available data from a large UK case-control cohort[@b16], we have conducted a comprehensive assessment of the contribution of genome-wide SNPs on the variance in liability to MS. The power of the approach used here is that contributions of genotypes at all available loci across the genome (in this case, 475,806), rather than only a set of identified MS risk loci, can be accounted for using this method. Thus, from our analysis, we conclude that approximately 30% of MS heritability is explained by variants on current GWAS arrays, including SNPs on chromosome 6, which alone account for \~8% and reflect the major contribution of the MHC. The role of the MHC in MS has long been known; specifically, *HLA-DRB1\*1501* confers a 2-fold increase in risk[@b13]. However, the underlying genetic architecture of MS is presumed to be polygenic, involving a large number of loci with smaller effects[@b22][@b23]. Our findings lend support to this notion, as we observed that the genetic contributions of SNPs on autosomes other than chromosome 6 were at least in part correlated to autosome length. However, this relationship was not significant, and not as convincing as that illustrated previously for other polygenic disorders[@b17][@b21]. This might hint at the possibility that some unidentified MS risk loci have slightly larger effects than others, which has been discussed recently[@b23]. Additionally, our study was smaller than that of Yang *et al.*[@b17] and Lee *et al.*[@b21], and thus would be comparatively underpowered.

Also notable, we observed that the majority of variation represented by GWAS SNPs was explained by common variants with MAFs over 0.1%, perhaps not surprisingly given that these outnumbered rare variants. This highlights both, the utility of GWAS arrays, which have placed much emphasis on the inclusion of common SNPs, and the fact that the use of larger sample sizes in GWAS should increase power and yield discoveries of additional risk loci, a point that has recently been noted in the context of schizophrenia[@b21]. Importantly though, this observation does not delimit the potentially significant role of rare variants in MS. For example, rare variants in *CYP27B1*, a gene essential to vitamin D synthesis, have been reported at low frequencies in MS patients, but not in controls (odds ratio = 4.7)[@b24]. Rare variants in the *TYK2* gene have also more recently been shown to influence MS risk[@b25]. Furthermore, we found that even after including the effects of over 400,000 SNPs in this cohort, most of the variance in MS liability remains unaccounted for. As has been discussed previously in the context of the "missing heritability" of complex diseases, one of the more likely explanations for this is that GWAS SNPs are in imperfect linkage disequilibrium (LD) with disease-causing variants[@b26]. Again, this points to the possible importance of rare variants, as allele frequency differences between causative alleles and genotyped SNPs impact LD, and may also implicate a potential role for structural variants (*e.g.*, large deletions or duplications), which are also only partially represented by neighboring SNPs, especially those that are multi-allelic and in regions of the genome characterized by segmental duplication[@b27]. Imputation based methods to increase the number of common variants tested can also be applied to datasets such as the one used here, but it has recently been observed in schizophrenia that the application of imputation methods only yielded an approximate 2% increase in heritability estimates[@b21].

In conclusion, we estimate that approximately 30% of genetic variation in liability to MS is captured by considering all genotyped SNPs simultaneously. The remaining missing heritability most likely reflects imperfect LD between causal variants and the genotyped SNPs.

Methods
=======

Genotypes for UK MS cases and controls were obtained from GWAS data recently generated by the International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium 2[@b16]. Estimates of the proportion of variance explained were calculated using the Genome-wide Complex Trait Analysis (GCTA) tool (<http://gump.qimr.edu.au/gcta/>)[@b17][@b18][@b19][@b20][@b21][@b28]. Genetic relatedness between individuals was conducted by principal component analysis using the GCTA tool; for this step, the threshold used to identify and remove related individuals was set to a pairwise genetic relationship value of \>0.025 (no individuals met this criteria). The top 20 eigenvectors from this analysis were then used as covariates in a restricted maximum likelihood analysis, again conducted within the GCTA tool; this was used to estimate the proportion of the variance explained by SNPs at the genome-wide level, and after partitioning SNP data by autosomes, MAFs, and quintiles. Assembly statistics for GRCh37 (hg19) were used to calculate autosome lengths (autosome length/total length of all autosomes). Association analysis of GWAS SNPs was conducted using PLINK (<http://pngu.mgh.harvard.edu/purcell/plink/>)[@b29].
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The proportion of variance in MS liability explained by SNPs partitioned by autosome (based on data from [Table 1](#t1){ref-type="table"}, excluding chr 6) relative to chromosome size, which was determined by dividing the length of each autosome by the sum of the lengths of all autosomes.](srep00770-f1){#f1}

![Contribution of GWAS SNPs partitioned by minor allele frequency.\
The total proportion of variance explained and standard errors for SNPs in each of five MAF bins. The number of SNPs included in each bin varied slightly (0.0--0.1%, n = 76046; 0.1--0.2%, n = 112435; 0.2--0.3%, n = 97482; 0.3--0.4%, n = 89704; 0.4--0.5%, n = 86625).](srep00770-f2){#f2}

![Contribution of GWAS SNPs partitioned by quintile.\
The total proportion of variance explained and standard errors for all SNPs tested after binning by quintile. The number of SNPs included in each quintile are as follows: 0.0--0.11%, n = 93079; 0.11--0.19%, n = 93074; 0.19--0.28%, n = 93076; 0.28--0.39%, n = 93089; 0.39--0.5%, n = 93116).](srep00770-f3){#f3}

###### Proportion of variance in MS liability explained per chromosome

  chr       Variance Explained   Standard Error
  -------- -------------------- ----------------
  **1**          0.011606           0.006417
  **2**          0.010433           0.006207
  **3**          0.021433           0.006129
  **4**          0.002666           0.005454
  **5**          0.021062           0.005955
  **6**          0.081112           0.007155
  **7**          0.013365           0.005453
  **8**          0.000678           0.004836
  **9**          0.006747           0.004896
  **10**         0.005168           0.004938
  **11**         0.003246           0.004827
  **12**         0.014884           0.005266
  **13**         0.005035           0.004257
  **14**         0.008067           0.004431
  **15**         0.01251            0.004326
  **16**         0.01705            0.004983
  **17**         0.015371           0.004533
  **18**         0.003484           0.004116
  **19**         0.007125           0.003979
  **20**         0.007533           0.004086
  **21**            0               0.002963
  **22**         0.003493           0.003107

###### Top SNPs from association analysis using UK GWAS data

  SNP           Chr   Position        Gene       *P* value
  ------------ ----- ----------- -------------- -----------
  rs6662618      1    92707999        GFI1       1.95E-06
  rs11809572     1    101122894      EXTL2       9.34E-06
  rs16849327     3    104970212   ZPLD1, ALCAM   7.17E-06
  rs16869665     4    20095328       SLIT2       3.14E-06
  rs2214543      7    10763417       NDUFA4      8.31E-06
  rs11984075     7    37403379       ELMO1       6.40E-07
  rs10749170    10    116302100      ABLIM1      5.67E-06
  rs10502249    11    122009461     UBASH3B      6.38E-06
  rs11069349    13    98572648       DOCK9       1.83E-06
  rs727263      13    98802109       UBAC2       3.26E-06
  rs7325747     13    98827933       UBAC2       4.36E-06
  rs9303323     17    37341634       TTC25       5.30E-06
  rs12952314    17    37398449       DNAJC7      8.18E-06
  rs7209012     17    37414849       DNAJC7      9.42E-07
  rs335516      18    28048065       MEP1B       5.99E-06

###### Contribution of associated SNPs from UK GWAS dataset to MS liability after binning by *P* value

  Bin: *P* value    \# of SNPs   Variance Explained   Standard Error
  ---------------- ------------ -------------------- ----------------
  1.00E-03             1195           0.176747           0.007402
  1.00E-04             429            0.108225           0.010376
  1.00E-05             298            0.069538           0.009827
  1.00E-06             244            0.044657           0.008199
  1.00E-10             149            0.035719           0.007789
